[Below are the Areas of Interest for consideration for GSK’s Assets:]

[RSV: updated on 30th May 2025]
• Studies to assess Adjuvanted, Respiratory Syncytial Virus Vaccine real-world effectiveness/impact in adult population at increased risk of RSV disease due to age, or underlying condition

[Herpes Zoster]
• Durability of protection against Herpes Zoster (HZ) (and its complications) in real world settings in immunocompromised individuals over longer term (≥7-8 years post vaccination with RZV)
• Clinical consequences of sub-clinical reactivation of Varicella Zoster Virus (VZV) (including but not limited to cardiovascular outcomes, dementia, and cognitive decline), and the potential impact of RZV on sub-clinical reactivation of VZV

[Neisseria]
• Immunogenicity and safety of 4CMenB or MenABCWY: Evaluating cross-protective features and/or novel dosing schemes
• Real world effectiveness of 4CMenB vaccine against diseases other than invasive meningococcal disease and gonorrhea

[Pn-MAPS]
• Studies to investigate the evolving serotype-specific pneumococcal disease burden (incl. epidemiological and/or economic endpoints) in adult and paediatric population